NVO
Novo Nordisk A/S
37.50$
+0.6%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +21.5% | +3.6% | -0.1% | +0.1% | +9.1% | +4.0% | +10.9% | +25.7% | +31.3% | +25.0% | +6.4% | |
| – | +11.2% | +6.1% | +2.6% | -0.1% | +14.0% | +4.2% | +13.0% | +20.2% | +25.7% | +24.5% | +32.0% | |
| – | +23.6% | +3.1% | -0.6% | +0.2% | +8.2% | +4.0% | +10.5% | +26.8% | +32.3% | +25.1% | +1.8% | |
| – | -1.1% | +7.0% | -3.8% | +5.6% | -4.0% | +8.7% | +14.9% | +35.3% | +34.9% | +48.1% | +8.3% | |
| – | +9.0% | +2.7% | -4.5% | +3.5% | +2.3% | -1.2% | +2.3% | +10.3% | +8.7% | +8.7% | +13.1% | |
| – | +6.4% | +9.2% | -2.3% | +4.1% | +5.3% | +4.9% | +12.7% | +26.0% | +27.4% | +25.1% | +4.3% | |
| – | +43.3% | -2.0% | +1.1% | -3.5% | +11.1% | +3.1% | +8.3% | +27.6% | +37.1% | +25.1% | -0.5% | |
| – | +71.8% | -3.0% | +38.5% | -5.6% | +158.8% | +77.3% | -25.9% | +30.8% | +43.4% | +202.6% | +156.5% | |
| – | +27.5% | +9.9% | +1.8% | -2.2% | +2.0% | +9.4% | +11.2% | +16.9% | +51.6% | +21.5% | +2.6% | |
| – | +13.2% | +14.5% | +6.9% | -14.8% | +6.8% | +14.5% | +3.0% | +19.6% | +55.1% | +24.8% | +7.3% | |
| – | +31.6% | +8.8% | +0.5% | +1.3% | +0.8% | +8.2% | +13.3% | +16.3% | +50.7% | +20.7% | +1.4% | |
| – | +23.8% | +9.8% | +1.8% | -0.6% | +5.4% | +8.9% | +10.3% | +17.4% | +49.3% | +29.1% | +5.9% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.